Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Chief Financial Officer | January 10, 2025 | January 13, 2025 |
| Sientra, Inc.SIEN · Entity 108294 | Chief Financial Officer | February 02, 2021 | February 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date January 10, 2025 · Filed January 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2035-01-10 | Direct | 175,000 |
Reported balance
After 2025-01-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-10 · Grant · Acquired 175,000 · Balance 175,000 F1: This option represents a right to purchase up to 175,000 shares of common stock, which option vests with respect to 43,750 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 75,000 |
Reported balance
After 2025-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-10 · Grant · Acquired 75,000 · Balance 75,000 F2: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10, 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase up to 175,000 shares of common stock, which option vests with respect to 43,750 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
F2: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
F3: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10, 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
Sientra, Inc.
Report date February 02, 2021 · Filed February 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,836 |
Reported balance
After 2021-02-02 transaction · row 1
1 source rowRow 1 · 2021-02-02 · Sale · Disposed 4,123 · Balance 131,836 F1: Sale of shares to satisfy the Reporting Person's tax withholding obligation upon the vesting of 10,000 Restricted Stock Units (RSUs). F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.88 to $4.96, inclusive. The Reporting Person undertakes to provide to Sientra, Inc., any security holder of Sientra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to satisfy the Reporting Person's tax withholding obligation upon the vesting of 10,000 Restricted Stock Units (RSUs).
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.88 to $4.96, inclusive. The Reporting Person undertakes to provide to Sientra, Inc., any security holder of Sientra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004918 · ownership.xml · derivative · entry 2 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10, 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. F3 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10, 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-25-004918 · ownership.xml · derivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 175,000 shares of common stock, which option vests with respect to 43,750 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 525,032 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000950170-24-130275 · ownership.xml · derivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,032 Underlying: Common Stock · 525,032 shares Expires 2033-05-01 F1 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 525,032 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 196,887 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 328,145 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 267,470 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000950170-24-073771 · ownership.xml · derivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,470 Underlying: Common Stock · 267,470 shares Expires 2033-05-01 F1 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 267,470 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 66,867 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 200,603 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:47 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 198,126 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026730 · doc4.xml · derivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,126 Underlying: Common Stock · 198,126 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 198,126 shares of Common Stock, which option vests with respect to 49,531 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:40 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 155,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006300 · doc4.xml · derivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:23 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 155,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006446 · doc4.xml · derivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 21:24 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | PurchaseCommon Stock | 10,000 | $8.87 | $88,700.00 |
DisclosureSEC source: 0000899243-21-023640 · doc4.xml · nonDerivative · entry 1 Little Paul Sean · CIK 0001749385 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple open market transactions in accordance with the Issuer's trading policies at prices ranging from $8.76 to $8.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 19:50 UTC | Sientra, Inc. SIEN · Entity 108294 | SaleCommon Stock | 4,123 | $4.91 | $20,256.30 |
DisclosureSEC source: 0001209191-21-007545 · doc4.xml · nonDerivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,836 F1 · shares: Sale of shares to satisfy the Reporting Person's tax withholding obligation upon the vesting of 10,000 Restricted Stock Units (RSUs). F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.88 to $4.96, inclusive. The Reporting Person undertakes to provide to Sientra, Inc., any security holder of Sientra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 19:55 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock (RSUs) | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054846 · doc4.xml · nonDerivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,959 F1 · shares: The Restricted Stock Units (RSUs) shall vest quarterly in five equal installments commencing on the first business day of Q1 2021 and ending on the first business day of Q1 2022. Read SEC document |
| September 03, 2020 Filed Sep 9, 2020 17:50 UTC | Sientra, Inc. SIEN · Entity 108294 | Tax withholdingCommon Stock | 5,763 | $3.54 | $20,401.02 |
DisclosureSEC source: 0001209191-20-049857 · doc4.xml · nonDerivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,959 F1 · shares: Disposition to the Issuer of shares to satisfy the Reporting Person's tax withholding obligation upon the vesting of 16,667 Restricted Stock Units (RSUs) which is exempt under Rule 16b-3. Read SEC document |
| May 01, 2020 Filed May 18, 2020 19:50 UTC | Sientra, Inc. SIEN · Entity 108294 | Tax withholdingCommon Stock | 3,169 | $2.52 | $7,985.88 |
DisclosureSEC source: 0001209191-20-030255 · doc4.xml · nonDerivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,722 F1 · shares: Disposition to the Issuer of shares to satisfy the Reporting Person's tax withholding obligation upon the vesting of 9,167 Restricted Stock Units (RSUs) which is exempt under Rule 16b-3. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 16:55 UTC | Sientra, Inc. SIEN · Entity 108294 | PurchaseCommon Stock | 17,391 | $5.75 | $99,998.25 |
DisclosureSEC source: 0001209191-19-036114 · doc4.xml · nonDerivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,891 Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 21:25 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock (RSUs) | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024181 · doc4.xml · nonDerivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 F1 · shares: The Restricted Stock Units (RSUs) vest over three (3) years as follows: one-third (1/3) shall vest on May 1, 2020, one-third (1/3) shall vest on May 3, 2021, and the remaining one-third (1/3) shall vest on May 2, 2022, subject to the Reporting Person's continued Service (as defined in the Sientra, Inc. 2014 Equity Incentive Plan) with the Issuer. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 21:35 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock (RSUs) | 50,000 | $21.78 | $1,089,000.00 |
DisclosureSEC source: 0001209191-18-046331 · doc4.xml · nonDerivative · entry 1 Little Paul Sean · CIK 0001749385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The Restricted Stock Units (RSUs) vest in three equal annual installments beginning August 6, 2018 subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.